Close Menu

cancer of unknown primary

The new consortium is aiming to make comprehensive genomic profiling accessible to advanced cancer patients in the US, to help inform their treatment decisions.

Using RNA and DNA sequencing to predict tumor site and detect gene alterations may allow patients with CUP to receive appropriate targeted treatment.

The companies will combine Neogene's expertise in targeting tumor neoantigens with Twist's DNA synthesis platform and product lines.

The study, supported by TargetCancer, Foundation Medicine, and Bayer, aims to match 400 patients with rare cancers to personalized treatments based on NGS.

The collaborators said they're creating a solution for pharmaceutical clients that will encompass everything from patient recruitment to regulatory approvals.

By allowing rare cancer patients to receive genomic profiling and treatments locally, the study investigators are hoping to expand access to molecularly informed care throughout the US.

The field is collecting evidence supporting genomics-guided care but experts are still awaiting prospective data and grappling with other challenges.

The project is collaborating with nine biopharma companies to combine more real-world clinical data with genomic data.

The study of cancer immunity biomarkers revealed complex immune profiles for most tumors, suggesting the need for customized combinations of immunotherapies.

The groups have written draft recommendations and are now asking for public comment from pathologists and other stakeholders.

Pages